Literature DB >> 20425022

New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.

Naomi Schlesinger1.   

Abstract

The rising prevalence of gout has led the pharmaceutical industry to rediscover what it had considered a forgotten disease. In April 2009, the Food and Drug Administration (FDA) approved febuxostat (Takeda Pharmaceuticals; Deerfield, IL), the first new urate-lowering gout drug in more than 40 years. In August 2009, the FDA approved colchicine for the treatment of acute gout. Several other pharmaceutical companies are also conducting clinical trials to test new drugs for acute and chronic gout. This article reviews new drugs and drugs in development in the management of acute and chronic gout.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20425022     DOI： 10.1007/s11926-010-0093-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  16 in total

1.  The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.

Authors:  Reza Khosravan; Brian A Grabowski; Michael D Mayer; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  J Clin Pharmacol       Date:  2006-01       Impact factor: 3.126

2.  Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.

Authors:  J D Moolenburgh; M K Reinders; T L Th A Jansen
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

3.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1.

Authors:  F S Di Giovine; S E Malawista; G Nuki; G W Duff
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

5.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

6.  Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.

Authors:  M A Becker; J Kisicki; R Khosravan; J Wu; D Mulford; B Hunt; P MacDonald; N Joseph-Ridge
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004-10       Impact factor: 1.381

7.  Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.

Authors:  H R Schumacher; M A Becker; E Lloyd; P A MacDonald; C Lademacher
Journal:  Rheumatology (Oxford)       Date:  2009-02       Impact factor: 7.580

Review 8.  Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors:  John S Bomalaski; Mike A Clark
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

9.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Authors:  John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz
Journal:  Arthritis Rheum       Date:  2008-09

10.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Authors:  R Terkeltaub; J S Sundy; H R Schumacher; F Murphy; S Bookbinder; S Biedermann; R Wu; S Mellis; A Radin
Journal:  Ann Rheum Dis       Date:  2009-07-26       Impact factor: 19.103
View more
  5 in total

Review 1.  [The etiology and management of gout].

Authors:  B Pazár Maldonado; A So
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

Review 2.  Functional characterization of a Colchicum autumnale L. double-bond reductase (CaDBR1) in colchicine biosynthesis.

Authors:  Zhiqiang Xiong; Liang Wang; Jingyi Sun; Xuefei Jiang; Hanqing Cong; Huapeng Sun; Fei Qiao
Journal:  Planta       Date:  2022-10-10       Impact factor: 4.540

3.  New advances in the treatment of gout: review of pegloticase.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Ther Clin Risk Manag       Date:  2010-10-27       Impact factor: 2.423

Review 4.  Renal transport of uric acid: evolving concepts and uncertainties.

Authors:  Ion Alexandru Bobulescu; Orson W Moe
Journal:  Adv Chronic Kidney Dis       Date:  2012-11       Impact factor: 3.620

Review 5.  What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Authors:  Barbara Nieradko-Iwanicka
Journal:  Reumatologia       Date:  2018-05-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.